Abstract: A device for treating a user's skin using plasma is provided. The device comprises a plasma generation assembly and a power supply. The plasma generation assembly comprises a discharge electrode including a first surface; a first dielectric material layer provided on the first surface of the discharge electrode and the first surface, a ground electrode surrounding the discharge electrode, and an insulation member spacing around the discharge electrode from the ground electrode. The power supply configured to apply power to the plasma generation assembly so that plasma is generated from the first surface of the discharge electrode to the ground electrode and between the first dielectric material layer and the user's skin.

Abstract: A semiconductor may include an active region, an epitaxial source/drain formed in and extending above the active region, and a first dielectric layer formed over a portion of the active region. The semiconductor may include a first metal gate and a second metal gate formed in the first dielectric layer, a second dielectric layer formed over the first dielectric layer and the second metal gate, and a titanium layer, without an intervening fluorine residual layer, formed on the metal gate and the epitaxial source/drain. The semiconductor may include a first metal layer formed on top of the titanium on the first metal gate, a second metal layer formed on top of the titanium layer on the epitaxial source/drain, and a third dielectric layer formed on the second dielectric layer. The semiconductor may include first and second vias formed in the third dielectric layer.

Abstract: The present invention is directed to nanoparticles comprising: (a) an inner core comprising oligomeric (?)-epigallocatechin gallate (OEGCG), (b) an outer core comprising a polyethylene glycol-epigallocatechin gallate conjugate (PEG-EGCG), and (c) a protein molecule of a drug substance encapsulated in the inner core; wherein at least 70% of the nanoparticles have a diameter between 50-300 nm. The present invention also provides a process for preparing the nanoparticles. The present invention further provides a method of treating cancer by administering to a subject in need thereof the nanoparticles of the present invention, in an amount effective to treat cancer.

Abstract: The present invention provides a pharmaceutical composition for treating rotavirus and/or respiratory syncytial virus infection and a method for preparing the same; wherein said pharmaceutical composition comprises a therapeutically effective amount of Spirulina extract and a pharmaceutically acceptable carrier. The Spirulina extract used in the present invention is extracted at a low temperature by the following steps: (a) adding an organic Spirulina powder into a hypotonic buffer solution and mixed well to obtain a mixture; (b) freezing the mixture from step (a) overnight at a temperature lower than 0° C.; (c) thawing the mixture from step (b); (d) separating and purifying the mixture from step (c) by a separator, and collecting blue fractions; and (e) spray drying the blue fractions from step (d).

Abstract: The present invention provides a pharmaceutical composition for treating rotavirus and/or respiratory syncytial virus infection and a method for preparing the same; wherein said pharmaceutical composition comprises a therapeutically effective amount of Spirulina extract and a pharmaceutically acceptable carrier. The Spirulina extract used in the present invention is extracted at a low temperature by the following steps: (a) adding an organic Spirulina powder into a hypotonic buffer solution and mixed well to obtain a mixture; (b) freezing the mixture from step (a) overnight at a temperature lower than 0° C.; (c) thawing the mixture from step (b); (d) separating and purifying the mixture from step (c) by a separator, and collecting blue fractions; and (e) spray drying the blue fractions from step (d).